| Publication | Date of Publication | Type |
|---|
| New results on optimal conditional error functions for adaptive two-stage designs | 2025-01-14 | Paper |
| Optimization of the two-stage group sequential three-arm gold-standard design for non-inferiority trials | 2024-10-30 | Paper |
| Comments on ``Adaptive sample size modification in clinical trials: start small then ask for more? | 2024-10-29 | Paper |
| A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation | 2024-10-29 | Paper |
| Optimal planning of adaptive two-stage designs | 2024-10-29 | Paper |
| Simulation and data-generation for random-effects network meta-analysis of binary outcome | 2024-10-28 | Paper |
| A variational approach to optimal two-stage designs | 2024-10-28 | Paper |
| What makes a biostatistician? | 2024-10-28 | Paper |
| Point estimation, confidence intervals, and \(P\)-values for optimal adaptive two-stage designs with normal endpoints | 2024-10-14 | Paper |
| Using real-world data to predict health outcomes -- the prediction design: application and sample size planning | 2024-08-28 | Paper |
| drugdevelopR | 2024-01-10 | Software |
| Optimization of adaptive designs with respect to a performance score | 2023-12-15 | Paper |
| Monotonicity conditions for avoiding counterintuitive decisions in basket trials | 2023-12-15 | Paper |
| Using independent cross‐sectional survey data to predict post‐migration health trajectories among refugees by estimating transition probabilities and their variances | 2023-12-15 | Paper |
| Categories, components, and techniques in a modular construction of basket trials for application and further research | 2023-11-27 | Paper |
| Optimization of the two‐stage group sequential three‐arm gold‐standard design for non‐inferiority trials | 2022-12-28 | Paper |
| A note on the shape of sample size functions of optimal adaptive two-stage designs | 2022-05-30 | Paper |
| Optimal planning of adaptive two‐stage designs | 2021-03-18 | Paper |
| The adoptr Package: Adaptive Optimal Designs for Clinical Trials in R | 2021-01-01 | Paper |
| Optimal designs for phase II/III drug development programs including methods for discounting of phase II results | 2020-10-09 | Paper |
| Sample Size Recalculation in Internal Pilot Study Designs: A Review | 2020-09-24 | Paper |
| A Bootstrap Procedure for Adaptive Selection of the Test Statistic in Flexible Two-Stage DesignsThis paper is based on a presentation given at the Workshop “Frontiers in Adaptive Designs”, 17.–18. 5. 2001, Vienna/Austria. | 2020-09-22 | Paper |
| A Comparison of Procedures for Adaptive Choice of Location Tests in Flexible Two-Stage Designs | 2020-09-22 | Paper |
| Blinded Sample Size Recalculation for Normally Distributed Outcomes Using Long- and Short-term Data | 2020-09-22 | Paper |
| Methods and Applications of Sample Size Calculation and Recalculation in Clinical Trials | 2020-08-17 | Paper |
| Adjustment for exploratory cut‐off selection in randomized clinical trials with survival endpoint | 2020-07-17 | Paper |
| Integrated evaluation of targeted and non‐targeted therapies in a network meta‐analysis | 2020-07-17 | Paper |
| Optimal Designs for Multi-Arm Phase II/III Drug Development Programs | 2020-01-30 | Paper |
| Optimal sample size allocation and go/no‐go decision rules for phase II/III programs where several phase III trials are performed | 2019-07-02 | Paper |
| A variational approach to optimal two‐stage designs | 2019-07-01 | Paper |
| A closer look at the effect of preliminary goodness‐of‐fit testing for normality for the one‐sample t‐test | 2018-12-05 | Paper |
| Consistency-adjusted alpha allocation methods for a time-to-event analysis of composite endpoints | 2018-11-23 | Paper |
| Optimal planning of phase II/III programs for clinical trials with multiple endpoints | 2018-04-26 | Paper |
| Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint | 2018-02-09 | Paper |
| An expected power approach for the assessment of composite endpoints and their components | 2017-06-30 | Paper |
| Assessing additional benefit in noninferiority trials | 2016-03-14 | Paper |
| Utility‐based optimization of phase II/III programs | 2015-08-09 | Paper |
| Optimal adaptive two-stage designs for phase II cancer clinical trials | 2013-11-19 | Paper |
| Sample Size Calculation and Blinded Sample Size Recalculation in Clinical Trials Where the Treatment Effect is Measured by the Relative Risk | 2013-06-13 | Paper |
| Sample size calculations for noninferiority trials with Poisson distributed count data | 2013-04-30 | Paper |
| Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials | 2012-11-19 | Paper |
| Curtailment in single-arm two-stage phase II oncology trials | 2012-09-13 | Paper |
| Blinded sample size recalculation in multicentre trials with normally distributed outcome | 2010-09-21 | Paper |
| Configural frequency analysis and association analyses in contingency tables | 2008-11-26 | Paper |
| Including long- and short-term data in blinded sample size recalculation for binary endpoints | 2008-11-26 | Paper |
| Monitoring Continuous Long-Term Outcomes in Adaptive Designs | 2005-07-18 | Paper |
| Procedures for testing multiple endpoints in clinical trials: an overview | 2002-02-18 | Paper |
| A note on change point estimation in dose-response trials | 2001-08-20 | Paper |
| APPROXIMATE SAMPLE SIZES FOR TESTING HYPOTHESES ABOUT THE RATIO AND DIFFERENCE OF TWO MEANS | 2001-06-05 | Paper |
| Configural Frequency Analysis (CFA) Revisited — a New Look at an Old Approach | 2000-03-21 | Paper |
| https://portal.mardi4nfdi.de/entity/Q4260090 | 2000-02-21 | Paper |
| https://portal.mardi4nfdi.de/entity/Q4260092 | 1999-11-09 | Paper |
| A unifying approach for confidence intervals and testing of equivalence and difference | 1998-03-11 | Paper |
| On the Use of the Upper Confidence Limit for the Variance from a Pilot Sample for Sample Size Determination | 1998-01-05 | Paper |
